Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.

Azpilikueta, Arantza; Agorreta, Jackeline; Labiano, Sara; Perez-Gracia, Jose Luis; Sánchez-Paulete, Alfonso R; Aznar, M Angela; Ajona, Daniel; Gil-Bazo, Ignacio; Larráyoz, Marta; Teijeira, Alvaro; Rodriguez-Ruiz, Maria E; Pio, Ruben; Montuenga, Luis M.; Melero, Ignacio

doi:10.1016/j.jtho.2016.01.013

Record: found
Abstract: found
Article: not found

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.

Author(s): Arantza Azpilikueta, Jackeline Agorreta, Sara Labiano, Jose Perez-Gracia, Alfonso Sánchez-Paulete, M Angela Aznar, Daniel Ajona, Ignacio Gil-Bazo, Marta Larráyoz, Alvaro Teijeira, Maria E Rodriguez-Ruiz, Ruben Pio, Luis Montuenga, Ignacio Melero

Publication date: 2016-04-01

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Publisher: Elsevier BV

Keywords: PD-L1, CD-137, Immunotherapy, Lung cancer, PD-1, Squamous

Read this article at

ScienceOpenPublisher PubMed

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Anti-programmed cell death 1 (anti-PD-1) and anti-programmed cell death ligand 1 (PD-L1) antagonist monoclonal antibodies (mAbs) against metastatic non-small cell lung cancer with special efficacy in patients with squamous cell lung cancer are being developed in the clinic. However, robust and reliable experimental models to test immunotherapeutic combinations in squamous lung tumors are still lacking.